Photo of Clare M. Tempany-Afdhal,  MB, BCh

Clare M. Tempany-Afdhal, MB, BCh

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-7858
Fax: (617) 732-6033


ctempany@bwh.harvard.edu

Clare M. Tempany-Afdhal, MB, BCh

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Radiology, Harvard Medical School
  • Ferenc Jolesz Chair of Research, Radiology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My major areas of research interest are MR imaging of the pelvis (specifically Prostate cancer) and image-guided therapy. As co-PI of the NCIGT I along with Ferenc Jolesz lead this team and direct the AMIGO facility. My lab is dedicated to prostate cancer imaging as it relates to diagnosis, staging, treatment monitoring and Image-guided Therapy (IGT). We have program in MR guided prostate biopsies for diagnosis and treatment monitoring. I lead several prospective trials involving clinical prostate multi-parametric prostate MR at 3.0T with an endorectal coil. Our lab works in all aspects from acquisition and optimization of multi-parametric 3T imaging, image processing, registration, and segmentation, navigation and image display. We are also working on many engineering challenges associated with guidance and access to the prostate. We have a program in enabling technologies, including robotics for MR guided interventions and MR guided Focused Ultrasound surgery(FUS). The latter is a major interest of our program at NCIGT and specifically in prostate cancer. We established MR guided in bore prostate biopsies for cancer diagnosis in 1997, sicne then have migrated this program to our wide-bore 3T MR and perform MR targeted and guided prostate biopsies in large cohorts of patients. Our research also involves MR image-guided focal therapyfor localized prostate cancer- MR guided cryotherapy or MR guided FUS, radiation delivery-namely EBRT and brachytherapy. We are involved in multi-disciplinary trials with colleagues in Oncology, Urology and Radiation Oncology and also national multi-center groups such as ACRIN.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Camacho A, Salah F, Bay CP, Waring J, Umeton R, Hirsch MS, Cole AP, Kibel AS, Loda M, Tempany CM, Fennessy FM. PI-RADS 3 score: A retrospective experience of clinically significant prostate cancer detection. BJUI Compass 2023; 4:473-481. PubMed
  • Burk KS, Naik S, Lacson R, Tuncali K, Lee LK, Tempany C, Cole AP, Trinh QD, Kibel AS, Khorasani R. MRI-Targeted, Systematic, or Combined Biopsy for Detecting Clinically Significant Prostate Cancer. J Am Coll Radiol 2023. PubMed
  • Naik S, Burk KS, Budiawan E, Lacson R, Lee LK, Fennessy FM, Tempany C, Cole AP, Trinh QD, Kibel AS, Khorasani R. Radiologists' Contribution to Variation in Detecting Clinically Significant Prostate Cancer in Men With Prostate MRI. J Am Coll Radiol 2022. PubMed
  • Lo WC, Bittencourt LK, Panda A, Jiang Y, Tokuda J, Seethamraju R, Tempany-Afdhal C, Obmann V, Wright K, Griswold M, Seiberlich N, Gulani V. Multicenter Repeatability and Reproducibility of MR Fingerprinting in Phantoms and in Prostatic Tissue. Magn Reson Med 2022; 88:1818-1827. PubMed
  • Ehdaie B, Tempany CM, Holland F, Sjoberg DD, Kibel AS, Trinh QD, Durack JC, Akin O, Vickers AJ, Scardino PT, Sperling D, Wong JYC, Yuh B, Woodrum DA, Mynderse LA, Raman SS, Pantuck AJ, Schiffman MH, McClure TD, Sonn GA, Ghanouni P. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol. 2022; 23:910-918. PubMed
  • Giganti F, Cole AP, Fennessy FM, Clinton T, Moreira PLDF, Bernardes MC, Westin CF, Krishnaswamy D, Fedorov A, Wollin DA, Langbein B, Frego N, Labban M, Badaoui JS, Chang SL, Briggs LG, Tokuda J, Ambrosi A, Kirkham A, Emberton M, Kasivisvanathan V, Moore CM, Allen C, Tempany CM. Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. Eur Radiol 2022. PubMed
  • Schmidt DR, Bhagwat M, Glazer DI, Chen MH, Moteabbed M, McMahon E, Loffredo MJ, Tempany CM, D'Amico AV. MRI-Based Radiotherapy Planning to Reduce Rectal Dose in Excess of Tolerance. Prostate Cancer 2022; 2022:7930744. PubMed
  • Meyer A, Mehrtash A, Rak M, Bashkanov O, Langbein B, Ziaei A, Kibel AS, Tempany CM, Hansen C, Tokuda J. Domain adaptation for segmentation of critical structures for prostate cancer therapy. Sci Rep 2021; 11:11480. PubMed
  • Langbein BJ, Szczepankiewicz F, Westin CF, Bay C, Maier SE, Kibel AS, Tempany CM, Fennessy FM. A Pilot Study of Multidimensional Diffusion MRI for Assessment of Tissue Heterogeneity in Prostate Cancer. Invest Radiol 2021. PubMed
  • Fennessy FM, Fedorov A, Vangel MG, Mulkern RV, Tretiakova M, Lis RT, Tempany C, Taplin ME. Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. Acad Radiol 2019. PubMed
  • Randall EC, Zadra G, Chetta P, Lopez BGC, Syamala S, Basu SS, Agar JN, Loda M, Tempany CM, Fennessy FM, Agar NYR. Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging. Mol Cancer Res 2019. PubMed
  • Aksit Ciris P, Chiou JG, Glazer DI, Chao TC, Tempany-Afdhal CM, Madore B, Maier SE. Accelerated Segmented Diffusion-Weighted Prostate Imaging for Higher Resolution, Higher Geometric Fidelity, and Multi-b Perfusion Estimation. Invest Radiol 2018. PubMed
  • Hassanzadeh E, Alessandrino F, Olubiyi OI, Glazer DI, Mulkern RV, Fedorov A, Tempany CM, Fennessy FM. Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer. Abdom Radiol (NY) 2017. PubMed
  • Kamran SC, Manuel MM, Cho LP, Damato AL, Schmidt EJ, Tempany C, Cormack RA, Viswanathan AN. Comparison of outcomes for MR-guided versus CT-guided high-dose-rate interstitial brachytherapy in women with locally advanced carcinoma of the cervix. Gynecol Oncol 2017. PubMed
  • Velez E, Fedorov A, Tuncali K, Olubiyi O, Allard CB, Kibel AS, Tempany CM. Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. Abdom Radiol (NY) 2017. PubMed
  • Mehrtash A, Sedghi A, Ghafoorian M, Taghipour M, Tempany CM, Wells WM, Kapur T, Mousavi P, Abolmaesumi P, Fedorov A. Classification of Clinical Significance of MRI Prostate Findings Using 3D Convolutional Neural Networks. Proc SPIE Int Soc Opt Eng 2017. PubMed
  • Glazer DI, Hassanzadeh E, Fedorov A, Olubiyi OI, Goldberger SS, Penzkofer T, Flood TA, Masry P, Mulkern RV, Hirsch MS, Tempany CM, Fennessy FM. Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdom Radiol (NY) 2016. PubMed
  • Hassanzadeh E, Glazer DI, Dunne RM, Fennessy FM, Harisinghani MG, Tempany CM. Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review. Abdom Radiol (NY) 2016. PubMed
  • Ciris PA, Balasubramanian M, Seethamraju RT, Tokuda J, Scalera J, Penzkofer T, Fennessy FM, Tempany-Afdhal CM, Tuncali K, Mulkern RV. Characterization of gradient echo signal decays in healthy and cancerous prostate at 3T improves with a Gaussian augmentation of the mono-exponential (GAME) model. NMR Biomed 2016; 29:999-1009. PubMed
  • Manuel MM, Cho LP, Catalano PJ, Damato AL, Miyamoto DT, Tempany CM, Schmidt EJ, Viswanathan AN. Outcomes with image-based interstitial brachytherapy for vaginal cancer. Radiother Oncol 2016. PubMed
  • Fedorov A, Tuncali K, Panych LP, Fairhurst J, Hassanzadeh E, Seethamraju RT, Tempany CM, Maier SE. Segmented diffusion-weighted imaging of the prostate: Application to transperineal in-bore 3T MR image-guided targeted biopsy. Magn Reson Imaging 2016; 34:1146-1154. PubMed
  • Tempany CM, Kapur T. Magnetic Resonance-Guided Interventions: The State of the Art. Magn Reson Imaging Clin N Am 2015; 23:xix. PubMed
  • Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2015. PubMed
  • Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, Padhani AR, Margolis D, Macura KJ, Haider MA, Cornud F, Choyke PL. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. Eur Urol 2015. PubMed
  • Fennessy FM, Fedorov A, Penzkofer T, Kim KW, Hirsch MS, Vangel MG, Masry P, Flood TA, Chang MC, Tempany CM, Mulkern RV, Gupta SN. Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging 2015. PubMed
  • Su H, Shang W, Cole G, Li G, Harrington K, Camilo A, Tokuda J, Tempany CM, Hata N, Fischer GS. Piezoelectrically Actuated Robotic System for MRI-Guided Prostate Percutaneous Therapy. IEEE ASME Trans Mechatron 2015; 20:1920-1932. PubMed
  • Silveira PC, Dunne R, Sainani NI, Lacson R, Silverman SG, Tempany CM, Khorasani R. Impact of an Information Technology-Enabled Initiative on the Quality of Prostate Multiparametric MRI Reports. Acad Radiol 2015; 22:827-33. PubMed
  • Tilak G, Tuncali K, Song SE, Tokuda J, Olubiyi O, Fennessy F, Fedorov A, Penzkofer T, Tempany C, Hata N. 3T MR-guided in-bore transperineal prostate biopsy: A comparison of robotic and manual needle-guidance templates. J Magn Reson Imaging 2015. PubMed
  • Eslami S, Shang W, Li G, Patel N, Fischer GS, Tokuda J, Hata N, Tempany CM, Iordachita I. In-bore prostate transperineal interventions with an MRI-guided parallel manipulator: system development and preliminary evaluation. Int J Med Robot 2015. PubMed
  • Fedorov A, Khallaghi S, Sánchez CA, Lasso A, Fels S, Tuncali K, Sugar EN, Kapur T, Zhang C, Wells W, Nguyen PL, Abolmaesumi P, Tempany C. Open-source image registration for MRI-TRUS fusion-guided prostate interventions. 2015. PubMed
  • Yamauchi FI, Penzkofer T, Fedorov A, Fennessy FM, Chu R, Maier SE, Tempany CM, Mulkern RV, Panych LP. Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence. Magn Reson Imaging 2015. PubMed
  • Fedorov A, Penzkofer T, Hirsch MS, Flood TA, Vangel MG, Masry P, Tempany CM, Mulkern RV, Fennessy FM. The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI. Acad Radiol 2015. PubMed
  • Xu H, Lasso A, Fedorov A, Tuncali K, Tempany C, Fichtinger G. Multi-slice-to-volume registration for MRI-guided transperineal prostate biopsy. 2015. PubMed
  • Tempany CM, Jayender J, Kapur T, Bueno R, Golby A, Agar N, Jolesz FA. Multimodal imaging for improved diagnosis and treatment of cancers. Cancer 2015. PubMed
  • Penzkofer T, Tuncali K, Fedorov A, Song SE, Tokuda J, Fennessy FM, Vangel MG, Kibel AS, Mulkern RV, Wells WM, Hata N, Tempany CM. Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology 2015. PubMed
  • Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV. The effect of differing Gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. Clin Genitourin Cancer 2014. PubMed
  • Fedorov A, Wells WM, Kikinis R, Tempany CM, Vangel MG. Application of tolerance limits to the characterization of image registration performance. IEEE Trans Med Imaging 2014. PubMed
  • Murciano-Goroff YR, Wolfsberger LD, Parekh A, Fennessy FM, Tuncali K, Orio PF, Niedermayr TR, Suh WW, Devlin PM, Tempany CM, Sugar EH, O'Farrell DA, Steele G, O'Leary M, Buzurovic I, Damato AL, Cormack RA, Fedorov AY, Nguyen PL. Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol 2014; 9:200. PubMed
  • Penzkofer T, Tempany-Afdhal CM. Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist's perspective. NMR Biomed 2014; 27:3-15. PubMed
  • Seifabadi R, Cho NB, Song SE, Tokuda J, Hata N, Tempany CM, Fichtinger G, Iordachita I. Accuracy study of a robotic system for MRI-guided prostate needle placement. Int J Med Robot 2013. PubMed
  • Hegde JV, Chen MH, Mulkern RV, Fennessy FM, D'Amico AV, Tempany CM. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Fennessy FM, Fedorov A, Gupta SN, Schmidt EJ, Tempany CM, Mulkern RV. Practical considerations in T1 mapping of prostate for dynamic contrast enhancement pharmacokinetic analyses. Magn Reson Imaging 2012; 30:1224-33. PubMed
  • Pursley J, Risholm P, Fedorov A, Tuncali K, Fennessy FM, Wells WM, Tempany CM, Cormack RA. A Bayesian nonrigid registration method to enhance intraoperative target definition in image-guided prostate procedures through uncertainty characterization. Med Phys 2012; 39:6858-67. PubMed
  • Tokuda J, Song SE, Fischer GS, Iordachita II, Seifabadi R, Cho NB, Tuncali K, Fichtinger G, Tempany CM, Hata N. Preclinical evaluation of an MRI-compatible pneumatic robot for angulated needle placement in transperineal prostate interventions. 2012; 7:949-57. PubMed
  • Fedorov A, Tuncali K, Fennessy FM, Tokuda J, Hata N, Wells WM, Kikinis R, Tempany CM. Image registration for targeted MRI-guided transperineal prostate biopsy. J Magn Reson Imaging 2012; 36:987-92. PubMed
  • Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol 2012; 188:1151-6. PubMed
  • Tokuda J, Tuncali K, Iordachita I, Song SE, Fedorov A, Oguro S, Lasso A, Fennessy FM, Tempany CM, Hata N. In-bore setup and software for 3T MRI-guided transperineal prostate biopsy. Phys Med Biol 2012; 57:5823-40. PubMed
  • Fennessy FM, Kong CY, Tempany CM, Swan JS. Quality-of-life assessment of fibroid treatment options and outcomes. Radiology 2011. PubMed
  • Tempany CM, McDannold NJ, Hynynen K, Jolesz FA. Focused ultrasound surgery in oncology: overview and principles. Radiology 2011; 259:39-56. PubMed
  • Su H, Camilo A, Cole GA, Hata N, Tempany CM, Fischer GS. High-field MRI-compatible needle placement robot for prostate interventions. Stud Health Technol Inform 2011; 163:623-9. PubMed
  • Song SE, Cho N, Tokuda J, Hata N, Tempany C, Fichtinger G, Iordachita I. Preliminary Evaluation of a MRI-compatible Modular Robotic System for MRI-guided Prostate Interventions. Proc IEEE RAS EMBS Int Conf Biomed Robot Biomechatron 2010; 2010:796-801. PubMed
  • Song SE, Cho NB, Fischer G, Hata N, Tempany C, Fichtinger G, Iordachita I. Development of a Pneumatic Robot for MRI-guided Transperineal Prostate Biopsy and Brachytherapy: New Approaches. 2010; 2010:2580-2585. PubMed
  • Fennessy FM, Tuncali K, Morrison PR, Tempany CM. MR imaging-guided interventions in the genitourinary tract: an evolving concept. Magn Reson Imaging Clin N Am 2010; 18:11-28. PubMed
  • Afnan J, Tempany CM. Update on prostate imaging. Urol Clin North Am 2010; 37:23-5, Table of Contents. PubMed
  • Tokuda J, Fischer GS, DiMaio SP, Gobbi DG, Csoma C, Mewes PW, Fichtinger G, Tempany CM, Hata N. Integrated navigation and control software system for MRI-guided robotic prostate interventions. Comput Med Imaging Graph 2010; 34:3-8. PubMed
  • Tokuda J, Fischer GS, Papademetris X, Yaniv Z, Ibanez L, Cheng P, Liu H, Blevins J, Arata J, Golby AJ, Kapur T, Pieper S, Burdette EC, Fichtinger G, Tempany CM, Hata N. OpenIGTLink: an open network protocol for image-guided therapy environment. Int J Med Robot 2009; 5:423-34. PubMed
  • Taran FA, Tempany CM, Regan L, Inbar Y, Revel A, Stewart EA, . Magnetic resonance-guided focused ultrasound (MRgFUS) compared with abdominal hysterectomy for treatment of uterine leiomyomas. Ultrasound Obstet Gynecol 2009; 34:572-8. PubMed
  • Oguro S, Tokuda J, Elhawary H, Haker S, Kikinis R, Tempany CM, Hata N. MRI signal intensity based B-spline nonrigid registration for pre- and intraoperative imaging during prostate brachytherapy. J Magn Reson Imaging 2009; 30:1052-8. PubMed
  • Weinreb JC,Blume JD,Coakley FV,Wheeler TM,Cormack JB,Sotto CK,Cho H,Kawashima A,Tempany-Afdhal CM,Macura KJ,Rosen M,Gerst SR,Kurhanewicz J. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251:122-33. PubMed
  • Viswanathan AN, Cormack R, Holloway CL, Tanaka C, O'farrell D, Devlin PM, Tempany C. Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer. Int J Radiat Oncol Biol Phys 2006; 66:91-9. PubMed
  • Mulkern RV, Barnes AS, Haker SJ, Hung YP, Rybicki FJ, Maier SE, Tempany CM. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006; 24:563-8. PubMed
  • Haker SJ, Mulkern RV, Roebuck JR, Barnes AS, Dimaio S, Hata N, Tempany CM. Magnetic resonance-guided prostate interventions. Top Magn Reson Imaging 2005; 16:355-68. PubMed
  • Zou KH, Fielding JR, Silverman SG, Tempany CM. Hypothesis testing I: proportions. Radiology 2003; 226:609-13. PubMed
  • Viswanathan AN, Szymonifka J, Tempany-Afdhal CM, O'Farrell DA, Cormack RA. A prospective trial of real-time magnetic resonance-guided catheter placement in interstitial gynecologic brachytherapy. Brachytherapy ; 12:240-7. PubMed
  • Nguyen PL,Chen RC,Clark JA,Cormack RA,Loffredo M,McMahon E,Nguyen AU,Suh WW,Tempany CM,D'Amico AV. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy ; 8:345-52. PubMed
Hide